Lisa Ebert

Research Interests

Biomarkers Cancer Therapy Cellular Immunology Tumour Immunology Cancer Biology and Clinical Oncology Immunology and Infection

Dr Lisa Ebert

Centre for Cancer Biology

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Available For Media Comment.

Associate Professor Lisa Ebert (B.Sc. (Hons), PhD) is a clinically-oriented cancer research scientist, with a particular interest in immunology and cancer immunotherapy. 
She completed her PhD at the University of Adelaide, before undertaking post-doctoral research at the University of Bern (Switzerland) and the Ludwig Institute for Cancer Research (Melbourne). During this time, she developed particular expertise in human immunology, cancer cell biology, multi-parameter flow cytometry and immune monitoring of cancer immunotherapy clinical trials.
Now, A/Prof Ebert is a Group Leader of Cancer Immunotherapy Research, within the Translational Oncology Laboratory at the Centre for Cancer Biology (CCB) - an alliance between Adelaide University and SA Pathology. Her research is aimed at understanding interactions between cancer cells and the immune system, and using this knowledge to improve cancer treatment. Key focus areas include developing new immunotherapy approaches for treating glioblastoma (brain tumours) and optimising the therapeutic efficacy of checkpoint inhibitors in melanoma. For further details on A/Prof Ebert's current research, refer to the CCB website: https://www.centreforcancerbiology.org.au/research/translational-oncology-laboratory/
A/Prof Ebert currently holds research grants from the NHMRC, Cancer Australia, Ray & Shirl Norman Cancer Research Trust, the Neurosurgical Research Foundation and others, and supervises several Honours, Masters and PhD students. Enquiries from prospective students with strong academic records are welcome.

Year Citation
2026 Gardam, B., Gargett, T., Nam, E., Khan, S., Ormsby, R. J., Poonnoose, S. I., . . . Ebert, L. M. (2026). Tumors Located in the Brain Impair the Frequency and Phenotype of Dendritic Cells in Blood and Tumor.. iScience, 29(3), 115160.
DOI Scopus1 WoS1 Europe PMC1
2026 Gardam, B., Nam, E., Kollis, P. M., Kilyen‐Coles, J., Lenin, S., Gliddon, B. L., . . . Gargett, T. (2026). A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors. Clinical & Translational Immunology, 15(4), 19 pages.
DOI
2026 Jarvis, A., Vincent, S., Hutchinson, A. D., Ebert, L. M., Brown, M. P., Marker, J., & Corsini, N. (2026). Patient Views on a Pre-treatment Blood Test to Predict Outcomes Following PD-1 Inhibitor Therapy: A Qualitative Study. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 7 pages.
DOI
2025 Palethorpe, H. M., Shard, C., Scheer, K. G., Ryan, C. P., Fouladzadeh, A., Wenholz, D., . . . Gomez, G. A. (2025). An Optimized Explant Organoid Method for Preclinical Brain Tumor Research. NEURO-ONCOLOGY, 27(Supplement_5), v167.
DOI
2024 Revesz, I. A., Joyce, P., Ebert, L. M., & Prestidge, C. A. (2024). Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. Clinical and Translational Immunology, 13(2, article no. e1492), 1-16.
DOI Scopus19 WoS18 Europe PMC9
2024 Gargett, T., Truong, N. T. H., Gardam, B., Yu, W., Ebert, L. M., Johnson, A., . . . Brown, M. P. (2024). Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. Journal for ImmunoTherapy of Cancer, 12(5), e008659-1-e008659-17.
DOI Scopus53 WoS50 Europe PMC35
2024 Gargett, T., & Ebert, L. M. (2024). Striking an alliance between T cells and macrophages for enhanced cancer immunotherapy. Immunology & Cell Biology, 102(7), 535-537.
DOI
2024 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M. N., Pitson, S. M., . . . Brown, M. P. (2024). Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma. Clinical & Translational Immunology, 13(7), e1519-1-e1519-20.
DOI Scopus13 WoS11 Europe PMC10
2024 Lertsumitkul, L., Iliopoulos, M., Wang, S. S., McArthur, S. J., Ebert, L. M., Davenport, A. J., . . . Jenkins, M. R. (2024). EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. Journal for ImmunoTherapy of Cancer, 12(8), e009486-1-e009486-14.
DOI Scopus19 WoS18 Europe PMC12
2023 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2023). Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small, 19(21), 2204956-1-2204956-14.
DOI Scopus10 WoS9 Europe PMC9
2023 Scheer, K. G., Ebert, L. M., Samuel, M. S., Bonder, C. S., & Gomez, G. A. (2023). Bevacizumab-Induced Hypertension in Glioblastoma Patients and Its Potential as a Modulator of Treatment Response. Hypertension, 80(8), 1590-1597.
DOI Scopus11 WoS11 Europe PMC11
2023 Pickering, C., Aiyetan, P., Xu, G., Mitchell, A., Rice, R., Najjar, Y. G. G., . . . Boland, G. M. M. (2023). Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Frontiers In Immunology, 14(1187332), 1-14.
DOI Scopus10 WoS11 Europe PMC8
2023 Kumari, S., Zemek, R. M., Palendira, U., & Ebert, L. M. (2023). Celebrating 100 years of Immunology & Cell Biology - a special focus on the field of tumor immunology in Australia. Immunology and Cell Biology, 101(9), 783-788.
DOI Scopus1 Europe PMC1
2023 Gardam, B., Gargett, T., Brown, M. P., & Ebert, L. M. (2023). Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma. Frontiers in Immunology, 14, 1261257-1-1261257-14.
DOI Scopus21 WoS19 Europe PMC14
2023 Stringer, B. W., De Silva, M. I., Greenberg, Z., Noreña Puerta, A., Adams, R., Milky, B., . . . Bardy, C. (2023). Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma. Science Advances, 9(43), eadf1332-1-eadf1332-20.
DOI Scopus16 WoS17 Europe PMC14
2023 Myo Min, K. K., Ffrench, C. B., McClure, B. J., Ortiz, M., Dorward, E. L., Samuel, M. S., . . . Bonder, C. S. (2023). Desmoglein-2 as a cancer modulator: friend or foe?. Frontiers in Oncology, 13(1327478), 1327478-1-1327478-15.
DOI Scopus18 WoS19 Europe PMC17
2022 Ebert, L. M., Vandyke, K., Johan, M. Z., DeNichilo, M., Tan, L. Y., Myo Min, K. K., . . . Bonder, C. S. (2022). Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 16(6), 1221-1240.
DOI Scopus15 WoS16 Europe PMC14
2022 Tan, L. Y., Cockshell, M. P., Moore, E., Myo Min, K. K., Ortiz, M., Johan, M. Z., . . . Bonder, C. S. (2022). Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. OncoImmunology, 11(1), e2043673-1-e2043673-18.
DOI Scopus23 WoS23 Europe PMC22
2022 Kollis, P. M., Ebert, L. M., Toubia, J., Bastow, C. R., Ormsby, R. J., Poonnoose, S. I., . . . Gargett, T. (2022). Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in immunology, 13, 850226-1-850226-19.
DOI Scopus24 WoS24 Europe PMC22
2022 Dmochowska, N., Milanova, V., Mukkamala, R., Chow, K. K., Pham, N. T. H., Srinivasarao, M., . . . Thierry, B. (2022). Nanoparticles targeted to fibroblast activation protein outperform PSMA for MRI delineation of primary prostate tumours.
DOI
2022 Gargett, T., Ebert, L. M., Truong, N. T. H., Kollis, P. M., Sedivakova, K., Yu, W., . . . Brown, M. P. (2022). GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma. Journal for ImmunoTherapy of Cancer, 10(9), 1-15.
DOI Scopus104 WoS101 Europe PMC96
2021 Yeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021). The role of cytokines and chemokines in shaping the immune microenvironment of glioblastoma: implications for immunotherapy. Cells, 10(3, article no. 607), 1-25.
DOI Scopus80 WoS70 Europe PMC57
2021 Oksdath Mansilla, M., Salazar-Hernandez, C., Perrin, S. L., Scheer, K. G., Cildir, G., Toubia, J., . . . Gomez, G. A. (2021). 3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC biomedical engineering, 3(6), 1-14.
DOI Europe PMC24
2021 Lenin, S., Ponthier, E., Scheer, K. G., Yeo, E. C. F., Tea, M. N., Ebert, L. M., . . . Gomez, G. A. (2021). A drug screening pipeline using 2D and 3D patient-derived in vitro models for pre-clinical analysis of therapy response in glioblastoma. International Journal of Molecular Sciences, 22(9), 4322-1-4322-27.
DOI Scopus48 WoS43 Europe PMC36
2021 Truong, N. T. H., Gargett, T., Brown, M. P., & Ebert, L. M. (2021). Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of car-t cell therapies. Cancers, 13(9, article no. 2225), 1-19.
DOI Scopus37 WoS34 Europe PMC29
2021 Martini, C., DeNichilo, M., King, D. P., Cockshell, M. P., Ebert, B., Dale, B., . . . Bonder, C. S. (2021). CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix. BMC Cancer, 21(1), 765-1-765-14.
DOI Scopus29 WoS29 Europe PMC24
2021 Brown, M. P., Ebert, L. M., & Gargett, T. (2021). Erratum: Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma.. Clinical & translational immunology, 10(8), e1331.
DOI Scopus1 WoS2 Europe PMC2
2020 Ebert, L. M., Yu, W., Gargett, T., Toubia, J., Kollis, P. M., Tea, M. N., . . . Brown, M. P. (2020). Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 9(10), 1-24.
DOI Scopus64 WoS60 Europe PMC55
2020 Martini, C., Thompson, E. J., Hyslop, S. R., Cockshell, M. P., Dale, B. J., Ebert, L. M., . . . Bonder, C. S. (2020). Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports, 10(1), 5869-1-5869-18.
DOI Scopus25 WoS21 Europe PMC21
2020 Zadeh Shirazi, A., Fornaciari, E., Bagherian, N. S., Ebert, L. M., Koszyca, B., & Gomez, G. A. (2020). DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images. Medical and Biological Engineering and Computing, 58(5), 1031-1045.
DOI Scopus57 WoS47 Europe PMC37
2019 Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019). Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochemical Society Transactions, 47(2), 625-638.
DOI Scopus135 WoS128 Europe PMC114
2019 Gargett, T., TRUONG, N., EBERT, L., YU, W., & BROWN, M. (2019). Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 21(6), 593-602.
DOI Scopus35 WoS36 Europe PMC37
2019 Brown, M. P., Ebert, L. M., & Gargett, T. (2019). Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and translational immunology, 8(5, article no. e1050), 1-20.
DOI Scopus38 WoS36 Europe PMC33
2019 Gomez, G. A., Oksdath, M., Brown, M. P., & Ebert, L. M. (2019). New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology. Translational Cancer Research, 8(Suppl. 6), S606-S611.
DOI Scopus10 WoS10 Europe PMC12
2018 Ebert, L. M., Yu, W., Gargett, T., & Brown, M. P. (2018). Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 46(2), 391-401.
DOI Scopus30 WoS29 Europe PMC25
2017 Davis, I. D., Quirk, J., Morris, L., Seddon, L., Tai, T. Y., Whitty, G., . . . Cebon, J. (2017). A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant. Immunotherapy, 9(3), 249-259.
DOI Scopus13 WoS14 Europe PMC13
2017 Tan, L. Y., Martini, C., Fridlender, Z. G., Bonder, C. S., Brown, M. P., & Ebert, L. M. (2017). Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 6(3), e134-1-e134-9.
DOI Scopus28 WoS29 Europe PMC25
2016 Ebert, L. M., Tan, L. Y., Johan, M. Z., Min, K. K. M., Cockshell, M. P., Parham, K. A., . . . Bonder, C. S. (2016). A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 19(4), 463-486.
DOI Scopus43 WoS44 Europe PMC37
2016 Tan, L., Mintoff, C., Johan, M., Ebert, B., Fedele, C., Zhang, Y., . . . Ebert, L. (2016). Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 7(29), 46492-46508.
DOI Scopus48 WoS49 Europe PMC47
2015 Pitman, M., Powell, J., Coolen, C., Moretti, P., Zebol, J., Pham, D., . . . Pitson, S. (2015). A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 6(9), 7065-7083.
DOI Scopus67 WoS67 Europe PMC62
2015 Moldenhauer, L., Cockshell, M., Frost, L., Parham, K., Tvorogov, D., Tan, L., . . . Bonder, C. (2015). Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties. Stem Cell Research, 14(3), 380-395.
DOI Scopus18 WoS19 Europe PMC15
2014 Tan, B., Anaka, M., Deb, S., Freyer, C., Ebert, L., Chueh, A., . . . Mariadason, J. (2014). FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget, 5(1), 264-276.
DOI Scopus48 WoS43 Europe PMC39
2013 Bonder, C., & Ebert, L. (2013). Fos-icking for control of angiogenesis: Increasing the longevity of peritoneal dialysis. Kidney International, 84(6), 1065-1067.
DOI Scopus6 WoS6 Europe PMC8
2013 Klein, O., Ebert, L. M., Zanker, D., Woods, K., Tan, B. S., Fucikova, J., . . . Cebon, J. (2013). Flt3 ligand expands CD4⁺FoxP3⁺ regulatory T cells in human subjects. European Journal of Immunology, 43(2), 533-539.
DOI Scopus54 WoS54 Europe PMC51
2012 Ebert, L. M., MacRaild, S. E., Zanker, D., Davis, I. D., Cebon, J., & Chen, W. (2012). A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS ONE, 7(10), e48424-1-e48424-10.
DOI Scopus55 WoS55 Europe PMC49
2012 Ebert, L. M., MacRaild, S. E., Davis, I. D., Cebon, J., & Chen, W. (2012). A novel method for detecting antigen-specific human regulatory T cells. Journal of Immunological Methods, 377(1-2), 56-61.
DOI Scopus5 WoS4 Europe PMC4
2010 Cebon, J., Knights, A., Ebert, L., Jackson, H., & Chen, W. (2010). Evaluation of cellular immune responses in cancer vaccine recipients: Lessons from NY-ESO-1. Expert Review of Vaccines, 9(6), 617-629.
DOI Scopus21 WoS18 Europe PMC17
2009 Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., . . . Cebon, J. (2009). Melan-a-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clinical Cancer Research, 15(7), 2507-2513.
DOI Scopus94 WoS88 Europe PMC72
2009 Nicholaou, T., Ebert, L. M., Davis, I. D., McArthur, G. A., Jackson, H., Dimopoulos, N., . . . Cebon, J. (2009). Regulatory T-Cell-mediated attenuation of T-Cell responses to the NY-ESO-1ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clinical Cancer Research, 15(6), 2166-2173.
DOI Scopus113 WoS102 Europe PMC94
2009 Ebert, L. M., Yu, C. L., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design. Cancer Research, 69(3), 1046-1054.
DOI Scopus50 WoS46 Europe PMC39
2009 Dimopoulos, N., Jackson, H. M., Ebert, L., Guillaume, P., Luescher, I. F., Ritter, G., & Chen, W. (2009). Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells. Journal of Immunological Methods, 340(1), 90-94.
DOI Scopus15 WoS15 Europe PMC15
2009 Ebert, L. M., Liu, Y. C., Clements, C. S., Robson, N. C., Jackson, H. M., Markby, J. L., . . . Chen, W. (2009). A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: Implications for cancer vaccine design (Cancer Research (2009) 69, (1046-54)). Cancer Research, 69(10), 4553.
DOI
2008 Ebert, L. M., Bee, S. T., Browning, J., Svobodova, S., Russell, S. E., Kirkpatrick, N., . . . Chen, W. (2008). The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Research, 68(8), 3001-3009.
DOI Scopus176 WoS155 Europe PMC142
2006 Schaerli, P., Ebert, L. M., & Moser, B. (2006). Comment on "The vast majority of CLA+ T cells are resident in normal skin" [1]. Journal of Immunology, 177(3), 1375-1376.
DOI Scopus5 WoS3 Europe PMC2
2006 Ebert, L. M., Meuter, S., & Moser, B. (2006). Homing and function of human skin γδ T cells and NK cells: Relevance for tumor surveillance. Journal of Immunology, 176(7), 4331-4336.
DOI Scopus221 WoS203 Europe PMC184
2006 Nicholaou, T., Ebert, L., Davis, I. D., Robson, N., Klein, O., Maraskovsky, E., . . . Cebon, J. (2006). Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1. Immunology and Cell Biology, 84(3), 303-317.
DOI Scopus101 WoS94 Europe PMC82
2005 Schaerli, P., Willimann, K., Ebert, L. M., Walz, A., & Moser, B. (2005). Cutaneous CXCL14 targets blood precursors to epidermal niches for langerhans cell differentiation. Immunity, 23(3), 331-342.
DOI Scopus130 WoS115 Europe PMC108
2004 Ebert, L. M., Horn, M. P., Lang, A. B., & Moser, B. (2004). B cells alter the phenotype and function of follicular-homing CXCR5+ T cells. European Journal of Immunology, 34(12), 3562-3571.
DOI Scopus36 WoS33 Europe PMC33
2004 Schaerli, P., Ebert, L., Willimann, K., Blaser, A., Roos, R. S., Loetscher, P., & Moser, B. (2004). A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells. Journal of Experimental Medicine, 199(9), 1265-1275.
DOI Scopus197 WoS175 Europe PMC154
2002 Ebert, L., & McColl, S. (2002). Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4⁺ T lymphocytes. Journal of Immunology, 168(1), 65-72.
DOI Scopus72 WoS70 Europe PMC60
2001 Ebert, L., & McColl, S. (2001). Coregulation of CXC chemokine receptor and CD4 expression on T lymphocytes during allogeneic activation. Journal of Immunology, 166(8), 4870-4878.
DOI Scopus41 WoS35 Europe PMC19
1999 Gale, L., & McColl, S. (1999). Chemokines: extracellular messengers for all occasions?. Bioessays, 21(1), 17-28.
DOI Scopus113 WoS108 Europe PMC89

Year Citation
2025 Scheer, K., Yeo, E., Shard, C., Lenin, S., Ormsby, R., Skarne, N., . . . Gomez, G. (2025). Growth rates of patient-derived tumor organoids reflect glioblastoma patients' heterogeneity in survival. In NEURO-ONCOLOGY Vol. 27 (pp. v479). OXFORD UNIV PRESS INC.
DOI
2023 Shard, C., Ormsby, R., Poonnoose, S., Toubia, J., Trim, P., Ebert, L., . . . Gomez, G. (2023). INVESTIGATING HOW GLIOBLASTOMA TUMOUR CELLS EXPLOIT THEIR METABOLIC MICROENVIRONMENT. In NEURO-ONCOLOGY Vol. 25 (pp. 1 page). CANADA, Vancouver: OXFORD UNIV PRESS INC.
2005 Ebert, L. M., Schaerli, P., & Moser, B. (2005). Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. In Molecular Immunology Vol. 42 (pp. 799-809). CANADA, Quebec City: PERGAMON-ELSEVIER SCIENCE LTD.
DOI Scopus256 WoS230 Europe PMC210
2003 Moser, B., & Ebert, L. (2003). Lymphocyte traffic control by chemokines: Follicular B helper T cells. In Immunology Letters Vol. 85 (pp. 105-112). DENMARK, ELSIMORE: ELSEVIER.
DOI Scopus46 WoS38 Europe PMC34

Year Citation
2026 Gomez, G., Scheer, K., Yeo, E., Shard, C., Palethorpe, H., Fouladzadeh, A., . . . Ebert, L. (2026). Growth rates of patient-derived tumor organoids reflect heterogeneity in tumor plasticity among glioblastoma patients. Poster session presented at the meeting of CANCER RESEARCH. PA, Philadelphia: AMER ASSOC CANCER RESEARCH.
DOI
2026 Nam, E., Gargett, T., Gardam, B., Kollis, P., Gliddon, B., Tea, M., . . . Ebert, L. (2026). Armouring GD2 chimeric antigen receptor (CAR)-t cells with chemokine receptors and interleukin (IL)-15 to treat glioblastoma. Poster session presented at the meeting of Abstracts of the 32nd ISCT Scientific Annual Meeting as published in Cytotherapy. United Kingdom: Elsevier.
DOI
2025 Lertsumitkul, L., Iliopoulos, M., Wang, S., McArthur, S., Ebert, L., Davenport, A., . . . Jenkins, M. (2025). EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. Poster session presented at the meeting of Abstracts from the Society for NeuroOncology Annual Meeting as published in Neuro-Oncology. United Kingdom: Oxford University Press.
DOI
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated desmoglein-2 surface expression is a predictor of poor outcome in multiple myeloma. Poster session presented at the meeting of Poster, SA Cancer Clinical Research Symposium.
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated desmoglein-2 surface expression is an independent predictor of poor outcome in multiple myeloma. Poster session presented at the meeting of Oral, Australian Society for Medical Research (ASMR) National Scientific Conference.
2024 Toomes, C., McClure, B., Best, G., Ebert, L., Vandyke, K., Cockshell, M., . . . Bonder, C. (2024). Elevated Desmoglein-2 Surface Expression Is an Independent Predictor of Poor Outcome in Multiple Myeloma. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Year Citation
2026 Ortiz, M., Ffrench, C., Webb, S., Toubia, J., Nataren, N., Dorward, E., . . . Bonder, C. (2026). Tumor Protein D54 (TPD54) regulates intracellular protein trafficking, cellular function and disease progression in melanoma.
DOI
2023 Yu, W., Truong, N. T. H., Polara, R., Gargett, T., Tea, M., Pitson, S., . . . Brown, M. (2023). Endogenous bystander killing mechanisms enhance the activity of novel FAP-specific CAR-T cells against glioblastoma.
DOI
  • Enhancing the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 01/08/2025 - 30/01/2027
  • Investigating dual targeting GD2 and FAP CAR T-cells for the treatment of brain malignancies, Neurosurgical Research Foundation, 01/10/2025 - 30/09/2026
  • Targeting tumour ecosystem interactions to overcome glioblastoma therapeutic resistance, Neurosurgical Research Foundation, 01/10/2025 - 30/09/2026
  • Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/07/2026
  • Exploiting blood vessels as conduits for the entry of therapeutic CAR-T cells into brain tumours, Neurosurgical Research Foundation, 02/10/2023 - 31/10/2025
  • Desmoglein-2; an unsuspected regulator of melanoma, NHMRC - Project Grant, 01/01/2019 - 31/12/2022
  • Development of a new therapy for glioblastoma based on chimeric antigen receptor (CAR)-T cells, Tour de Cure Ltd, 01/01/2021 - 31/12/2022
  • Validation of a novel therapeutic target in multiple myeloma, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017
  • Checkpoint blockade immunotherapy in melanoma: getting tumour-killing T cells to their site of action, Royal Adelaide Hospital, 01/01/2016 - 31/03/2017

Date Role Research Topic Program Degree Type Student Load Student Name
2026 Principal Supervisor Understanding CD15s regulation on human T cells and its impact on anti-PD1 immunotherapy in melanoma patients Doctor of Philosophy Doctorate Full Time Miss Rachael Stone
2026 Principal Supervisor Understanding CD15s regulation on human T cells and its impact on anti-PD1 immunotherapy in melanoma patients Doctor of Philosophy Doctorate Full Time Miss Rachael Stone
2025 Co-Supervisor To identify biomarkers of patient response to CAR-T cell therapy Doctor of Philosophy Doctorate Full Time Mr Ryan U Theen Chin
2025 Principal Supervisor Pre-clinical development of FAP-targeting CAR-T cells for the treatment of Glioblastoma. Doctor of Philosophy Doctorate Full Time Miss Jasmine Elizabeth Kilyen-Coles
2025 Co-Supervisor To identify biomarkers of patient response to CAR-T cell therapy Doctor of Philosophy Doctorate Full Time Mr Ryan U Theen Chin
2025 Co-Supervisor A bioengineered "brain tumour on a chip" recapitulating treatment resistance towards precision radiotherapy with nanoparticulate radiosensitisers - Doctorate Full Time Ms Esmee Broekhuizen
2025 Principal Supervisor Pre-clinical development of FAP-targeting CAR-T cells for the treatment of Glioblastoma. Doctor of Philosophy Doctorate Full Time Miss Jasmine Elizabeth Kilyen-Coles
2025 Co-Supervisor A bioengineered "brain tumour on a chip" recapitulating treatment resistance towards precision radiotherapy with nanoparticulate radiosensitisers Doctor of Philosophy Doctorate Full Time Ms Esmee Broekhuizen
2025 Co-Supervisor From Bench to Bottleneck: a Physiologically and Clinically Relevant Model of Paediatric Low-Grade Glioma Doctor of Philosophy Doctorate Full Time Ms Esmee Broekhuizen
2024 Co-Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Miss Abbey Rose Marshall
2024 Co-Supervisor Investigating dual targeting CAR-T cells for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Ms Abbey Rose Marshall
2023 Principal Supervisor Investigating the Dendritic Cell - T Cell Axis in Glioblastoma to Explore New Combination Immunotherapy Treatment Options Doctor of Philosophy Doctorate Full Time Mr Bryan Gardam
2023 Principal Supervisor Enhancing cancer immunotherapy success by efficient recruitment of T cells to solid tumours Doctor of Philosophy Doctorate Full Time Ms Resty Nabeeta
2023 Co-Supervisor 110496 - Lipid-based Nanocarrier Enabled Delivery for Improved T-cell Immunotherapy Doctor of Philosophy Doctorate Full Time Miss Isabella Ampelia Revesz
2022 Principal Supervisor Identifying optimal immunotherapy combinations for the treatment of brain tumours Doctor of Philosophy Doctorate Full Time Mr Chris Nam
2021 Co-Supervisor Tumour protein D54 as a regulator of melanoma progression Doctor of Philosophy Doctorate Full Time Mr Michael Ortiz

Date Role Research Topic Program Degree Type Student Load Student Name
2023 - 2026 Principal Supervisor Investigating the Dendritic Cell-T Cell Axis in Glioblastoma to Explore New Combination Immunotherapy Treatment Options Doctor of Philosophy Doctorate Full Time Mr Bryan Gardam
2021 - 2026 Co-Supervisor Tumour protein D54 as a regulator of melanoma progression Doctor of Philosophy Doctorate Full Time Michael Ortiz
2019 - 2025 Principal Supervisor Preclinical development of GD2 CAR-T cell therapy for glioblastoma Doctor of Philosophy Doctorate Part Time Miss Erica Yeo
2017 - 2020 Co-Supervisor Optimising CAR T cell manufacturing for solid cancers Master of Medical Science Master Part Time Ms Nga Truong
2014 - 2018 Principal Supervisor Vasculogenic mimicry: regulation and function in melanoma Doctor of Philosophy Doctorate Full Time Miss Lih Tan
2014 - 2018 Co-Supervisor The role of platelets in vasculogenic mimicry Doctor of Philosophy Doctorate Part Time Miss Carmela Martino

Connect With Me

External Profiles

Other Links